Skip to main content
KYTX logo

Kyverna Therapeutics, Inc.

KYTXNASDAQHealthcareBiotechnology

$5.27Today:- (-)1Y −10.47%

As of Oct 26, 2026 close

Market cap
$320.93M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.61$13.67
Volume (live)
-
Avg. volume (3M)
951.64K

Kyverna Therapeutics (KYTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Kyverna Therapeutics used $153.71M of cash in operating activities and spent $5.00K on capital expenditures. That left free cash flow of −$153.72M.

Kyverna Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kyverna Therapeutics, Inc. (KYTX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-161.31-127.48-60.37-28.89-26.35
Depreciation & Amortization1.802.131.711.050.59
Stock Based Compensation10.088.362.220.930.25
Change in Working Capital-1.087.863.42-10.33-4.49
Change in Accounts Payable0.540.744.080.680.01
Change in Other Working Capital-1.622.541.72-2.61-1.37
Other Operating Activities-3.212.541.721.137.85
Net Cash from Operating Activities-153.71-114.25-52.41-36.11-22.16
Investing Activities
Capital Expenditures0.00-2.21-0.62-0.77-1.29
Acquisitions0.070.000.000.000.00
Purchases of Investments-364.62-490.00-54.85-56.500.00
Sales/Maturities of Investments398.81331.3046.6843.170.00
Other Investing Activities5.767.660.000.000.00
Net Cash from Investing Activities40.02-160.90-8.79-14.10-1.29
Financing Activities
Debt Repayment23.89-0.96-0.78-0.25-0.04
Common Stock Issued117.42341.170.650.180.03
Other Financing Activities-0.14-3.36-1.65-0.25-0.04
Net Cash from Financing Activities141.17337.1158.1211.8872.52
Summary
Net Change in Cash27.4761.96-3.08-38.3349.08
Cash at Beginning of Period97.1735.2138.2976.6227.54
Cash at End of Period124.6497.1735.2138.2976.62
Free Cash Flow-153.72-116.46-53.03-36.88-23.44
Supplemental Disclosures
Interest Paid-0.140.190.070.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kyverna Therapeutics Cash Flow

What is Kyverna Therapeutics's free cash flow?

Kyverna Therapeutics had negative free cash flow of $153.72M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$153.71M minus $5.00K of capital expenditures.

How much does Kyverna Therapeutics spend on capital expenditures?

Kyverna Therapeutics spent $5.00K on capital expenditures in fiscal 2025, compared with $2.21M a year earlier.

Does Kyverna Therapeutics pay dividends or buy back shares?

Kyverna Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition